AlloDerm Versus Cortiva: A Multicenter Pooled Analysis of Clinical and Economic Outcomes in Breast Reconstruction

Authors: Tanas Y, Harris P, Gasper G, Cato L, Cervantes Valadez S, Rashidi K, Nguyen P, Wang J, Swed S, Zak P

Affiliation: Houston Methodist Hospital

Journal: Plastic and Reconstructive Surgery Global Open, February 2026

PMID: 41710187

Key takeaways

• This is a PRISMA-based systematic review and meta-analysis of 5 comparative breast reconstruction studies including 1180 reconstructions in 1072 patients.

• No statistically significant clinical difference was found between AlloDerm and Cortiva for seroma, hematoma, infection, mastectomy-flap necrosis, reoperation, drain duration, or BREAST-Q physical well-being.

• The strongest signal is economic, not clinical: Cortiva was reported as 10% to 22% cheaper per sheet and, in the strongest cost studies, associated with 44% to 56% lower per-breast episode cost.

Background

AlloDerm and Cortiva are both human acellular dermal matrices used to support implant-based breast reconstruction. Brand-level comparative evidence has been limited despite widespread use and meaningful cost differences in real-world procurement.

Objective

To compare short-term complications, patient-reported physical well-being, and cost outcomes between AlloDerm and Cortiva in immediate and delayed prosthetic breast reconstruction.

Methods

• Systematic review and meta-analysis, prospectively registered in PROSPERO and reported per PRISMA 2020.

• Databases searched: PubMed, Scopus, and Web of Science in 2025 for adult head-to-head comparative studies of AlloDerm versus Cortiva in implant-based breast reconstruction.

• Included designs: 1 blinded randomized trial, 1 interim randomized trial, and 3 observational comparative cohorts.

• Outcomes pooled with random-effects models: seroma, hematoma, infection, mastectomy-flap necrosis, unplanned reoperation, drain duration, BREAST-Q physical well-being, and cost.

• Operative settings were heterogeneous: mostly prepectoral in 3 studies, with mixed or subpectoral tissue-expander cases in the others.

• Follow-up ranged from 30 days to 42 months, and only 2 studies extended past 24 months.

Results

• No significant difference in seroma: OR 1.50, 95% CI 0.56 to 4.06, P = 0.42.

• No significant difference in hematoma: OR 1.25, 95% CI 0.38 to 4.13, P = 0.71.

• No significant difference in infection: OR 1.06, 95% CI 0.66 to 1.69, P = 0.82.

• No significant difference in mastectomy-flap necrosis: OR 1.34, 95% CI 0.13 to 13.59, P = 0.80.

• Reoperation was similar: OR 0.89, 95% CI 0.35 to 2.30, P = 0.81.

• BREAST-Q physical well-being showed no significant difference: MD -1.61, 95% CI -4.53 to 1.30, P = 0.28.

• Drain duration was similar: MD -0.21 days, 95% CI -0.94 to 0.53, P = 0.58.

• The major distinction was cost. In the included economic analyses, Cortiva cost less per cm² and had substantially lower material and total per-breast episode cost in the strongest comparative cost study.

• The savings appear to come mostly from purchase price rather than fewer downstream complications.

• The highest-quality included randomized trial found Cortiva to be noninferior to AlloDerm, with directionally lower seroma and lower variable cost.

• The strongest comparative cohort similarly found comparable clinical outcomes but lower material and total episode cost with Cortiva.

Conclusion

AlloDerm and Cortiva appear clinically comparable in the short term, but Cortiva seems more economical.

Strengths and limitations

• Best available brand-to-brand synthesis on this specific question, and it includes the highest-quality head-to-head randomized evidence currently available.

• Includes both clinical outcomes and cost, which is especially important when products appear functionally similar.

• The evidence base is still shallow: mostly nonrandomized data, moderate-to-high heterogeneity for some endpoints, and likely underpowering many variables.

• Long-term outcomes remain a major blind spot. The study cannot meaningfully answer questions about capsular contracture, aesthetic revision, fat grafting burden, or durable patient satisfaction.

• One indirect abdominal wall reconstruction study was used for cost context, which weakens breast-specific inference.

Clinical relevance

For practicing reconstructive surgeons, this paper supports a straightforward message: if you already use human ADM and your choice is AlloDerm versus Cortiva, you should not expect a meaningful short-term clinical difference based on current evidence. The practical differentiator is likely your local purchasing contract.

Editorial Notes

This study's biggest limitation is the lack of long-term outcomes that matter most to surgeons, including capsular contracture, implant positioning, revision rates, and aesthetic durability. Would these findings persist under stricter same-plane, same-stage, same-sheet-area, and same-thickness protocols?